Colosteo

Osteoporosis constitutes a major public health concern. The use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. Colostrum is a promising agent against bone loss since it has natural constituents that are directly involved in bone metabolism. As a nutraceutical, colostrum confers an advantage over pharmacological drugs since it can avoid side effects. However, the possibility of its use as a nutraceutical agent for osteoporosis have only received attention within the scientific community. The knowledge produced on the effects of colostrum on bone metabolism has not yet been transferred to the market because academic institutions lack on expertise to create a new product. On the other hand, industry has knowledge on product development, but lack expertise on research skills. COLOSTEO aims to fill in this gap by creating an intersectorial collaboration to exchange knowledge and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis. This aim will be achieved by bridging two academic with two industrial institutions that through intersectorial secondments will exchange knowledge, ideas and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis. This project initiated on 1/1/2018 and is set to finish on 31/12/2021.